Background: The present research aimed to investigate the efficacy of a multifaceted
Introduction
Bipolar disorder (BD) causes significant disability in personal and social domains, and with a prevalence of 1-2% (Merikangas et al., 2007) , it imposes a huge burden on society.
According to a recent meta-analysis, patients with BD spend more than 40% of their time ill (Forte et al., 2015) . Despite the fact that it is possible to control the symptoms of BD using medication, low levels of adherence is a substantial problem and have been reported in up to 50% of cases (Geddes and Miklowitz, 2013 , Lacro et al., 2002 , Lingam and Scott, 2002 , Scott and Pope, 2002a . Patients with BD show a much lower rate of routinely and consciously taking prescribed medicines (35%) than patients with, for example, schizophrenia (50-60%).
Consequently, patients with BD tend to have poorer health outcomes, including lower levels of daily functioning, psychological health, and quality of life (QoL) (Dean et al., 2004 , IsHak et al., 2012 . Therefore, it is important to develop interventions that can promote medication adherence (MA).
Effective interventions are likely to be those that target modifiable determinants of nonadherence (Berk et al., 2004) , such as beliefs and attitudes (Berk et al., 2004 , Lingam and Scott, 2002 , Scott and Pope, 2002a . As a result, a few studies (Bauer et al., 2006a , b, Cakir et al., 2009 , Javadpour et al., 2013 have designed behavioral interventions (e.g., behavioral therapy, family reliant treatments, psychosocial education, and interpersonal therapies) in an effort to promote MA. For example, Parsons et al. used behavioral therapy to improve MA in HIVpositive people and found reductions in substance abuse (although no significant change in MA, perhaps due to the relatively small sample, (Folco et al., 2012) . In another study on BD patients, eight sessions of psychoeducation yielded better MA and also QoL among participants in the intervention group when followed up 2 years later (Javadpour et al., 2013) . Other interventions designed to promote MA have focused on increasing communication and support provided by family members to patients, and this strategy is popular for the treatment of mental disorders such as schizophrenia (Rollnick et al., 2008) .
However, previous studies that have addressed the challenge of MA in patients with BD have been somewhat limited in their methods. To the best of our knowledge, all previous studies have only used one type of intervention (namely, psychoeducation) in addition to usual care (Rouget and Aubry, 2007) . The beneficial effects of psychoeducation for patients with BD have been demonstrated on a number of different outcomes, including MA, insight improvement, and a reduction in symptoms relief for people with BD (Bilderbeck et al., 2016 , Hidalgo-Mazzei et al., 2016 , Kallestad et al., 2016 , Rouget and Aubry, 2007 . Similar interventions have also been shown to reduce the burden of care, as well as distress among family members (Bermúdez-Ampudia et al., 2016 , Hubbard et al., 2016 . Given that patients with BD can differ in their responses to the same intervention (Culpepper, 2014) , it is possible that a multifaceted intervention that targets various reasons for non-adherence might result in even better outcomes.
A second problem with the evidence-base to date is that many (but not all) previous studies (Bauer et al., 2006b , Cakir et al., 2009 , Javadpour et al., 2013 have primarily used selfreported questionnaires to measure MA. However, self-reported outcomes may be biased by social desirability effects (e.g., patients with BD may feel obligated to report that they have followed the instructions of a health professional) and / or memory problems (e.g., patients with BD may not remember whether they have taken their medication). Using objective measures of adherence, such as serum levels of mood stabilizers, can reduce the possibility of bias and provide a more accurate estimate of the effect of an intervention on MA.
The Present Research
Given the importance of developing interventions to promote MA among people with BD and the limitations of the current evidence, the present research sought to develop a multifaceted intervention and examine the effects of the intervention on self-report and objective indices of MA, as well as secondary outcomes that include potential mediators of treatment effects. The intervention was centered around motivational interviewing (MI), a client-centered approach that seeks to change attitudes and behavior (Lundahl et al., 2013) . Although originally developed for reducing alcohol dependence, the use of MI has been rapidly expanded to other health-related domains. Indeed, a meta-analysis of 48 studies has shown that MI is an effective way to promote changes in behavior across multiple healthcare domains such as diabetes, obesity, smoking, and HIV treatment (Lundahl et al., 2013) . In recent years, MI has also been used to improve MA in conditions that require long-term commitment to treatment such as schizophrenia and acute coronary syndrome (Depp et al., 2007) . Nevertheless, there is scant evidence on the effect of MI in improving MA in patients with BD.
In addition to MI, we also investigated the idea that interventions might benefit from including family members, because family members are likely to support patients with BD in taking their medications (Williams and Wright, 2014) especially in the East, where culture substantially values the family relationship (Tsai et al., 2015) .
Despite the importance of MA (or lack thereof) in patients with BD, a systematic review of studies testing the efficacy of interventions designed to improve MA in BD found only five studies whose primary outcome was adherence. A meta-analysis of 18 studies showed an OR of 2.27(95%CI=1.45-3.56) for improvement in adherence in the intervention group compared to control groups (MacDonald et al., 2016) .To the best of our knowledge, our study is the most comprehensive study to date of a multifaceted intervention to improve the adherence in patients with BD.
Methods
Design and study population A multicenter, randomized, observer-blind, controlled, parallel-group trial was conducted in ten academic centers in Iran: Tehran (three centers), Qazvin, Ahvaz, Semnan, Zanjan, Tabriz, Zahedan, and Mashahd between September 2014 and October 2016. Persian speaking patients were eligible if they; 1) met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for bipolar I or II disorder simultaneously confirmed by the administration of Structured Clinical Interview (SCID); 2) were 18 years or older; 3) were being treated with a mood stabilizer; and 4) were not attending weekly or biweekly psychotherapy. Patients were excluded if they; 1) had a DSM-IV-TR diagnosis of drug or alcohol misuse disorders (five independent researchers administered a semi-structured interview and a structured interview based on DSM-IV-TR criteria for alcohol abuse, alcohol dependence and also substance abuse excluding nicotine); 2) showed evidence of severe DSM-IV-TR borderline personality; 3) needed to change the type and/or the dose of a mood stabilizer; 4) were pregnant or planned to be pregnant in the next year; 5) were unable and/or unwilling to provide a written informed consent; 6) had any organic cerebral cause for bipolar disorder (e.g., multiple sclerosis or stroke); or 7)
had an intellectual disability. Figure 1 shows the flow of participants through the trial, including the number of patients excluded for the various reasons detailed above.
All patients and their family members provided informed consent before participating in the study. The protocol was prepared in accordance with the Ottawa Statement, the Helsinki Declaration and Good Clinical Practice, and ethical review committees at each of the sites approved the trial. The trial was registered in the clinicaltrials.gov registry (https://clinicaltrials.gov/ct2/show/NCT02241863).
Intervention
A multifaceted intervention was developed in an effort to improve MA and clinical outcomes. The intervention included two components: a) Psychoeducation for the patients and their family members and b) motivational interviewing. Detailed information on the intervention is provided in the online supplementary materials.
MI integrity/fidelity
To assess treatment fidelity, all sessions were recorded and transcribed. Two trained research assistants reviewed each recording in order to determine the proportion of the intervention elements that were covered by the facilitators. The Motivational Interview Treatment Integrity (MITI) scale was used to assess the integrity of the MI in the EXP group.
Two separate aspects of treatment fidelity were taken into account: (i) Global variables (i.e., empathy, evocation, collaboration, autonomy/support, and direction) and (ii) behavior counts (i.e., giving information, asking open-ended and closed-ended questions, providing simple and complex reflections, and making other statements categorized as MI adherent or not). Inter-rater reliability was computed using intraclass correlation coefficients (ICCs) in a two-way mixed model with absolute agreement. The ICCs were found to be adequate for global measures, behavior counts, and summary scores (ICCs ranged from 0.69 to 0.92, as reported in online Supplementary Table S1 ).
Usual Care
Patients in the usual care (UC) group received the usual care that is provided to people with severe mental illnesses in Iran, which is mainly based on pharmacological interventions and follow-up visits to address and deal with adjustments to the dosage and / or nature of medications and management of side effects. There are no national guidelines for the provision of psychosocial services such as occupational rehabilitation, supported employment, social skills education and family support. However, during last decade, there has been a growing interest in providing these services, such that informal psycho-education about social skills and compliance with treatment may be provided on some occasions.
Outcomes
The primary outcome measure was medication adherence (MA) measured using selfreport and objective indices. Secondary outcomes included measures of beliefs and psychosocial health. All outcomes were measured three times (at baseline before the intervention, and then one and six months after the intervention) using the measures described below. Clinical status was assessed using the Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S; (Spearing et al., 1997 ) and the Young Mania Rating Scale (YMRS; (Young et al., 1978) and the Montgomery Åsberg Depression Rating Scale (MADRS; (Montgomery and Asberg, 1979) were used to assess manic and depressive symptoms, respectively. The clinical measures were administrated by five psychiatrists who were blinded to the treatment allocation.
Medication Adherence Rating Scale (MARS)
The MARS was used to measure the primary outcome in the study; namely, MA. Patients were asked to rate the extent to which five statements describing non-adherent behaviors, such as forgetting to take medicines or missing a dose, apply to them on a 5-point Likert scale (1: Always to 5: Never) e.g., Do you ever forget to take your medication? (O'Carroll et al., 2011) . The MARS has been shown to be relatively unaffected by social desirability effects (O'Carroll et al., 2011) , and the Persian translation of the MARS (Pakpour et al., 2014) demonstrates unidimensionality and high levels of internal consistency (Cronbach's =0.84).
Plasma level of mood stabilizer
The primary outcome of MA was also assessed using objective indices. Specifically, plasma levels of mood stabilizers were obtained from biochemistry laboratories at each center, and levels of three mood stabilizers were assayed: Lithium, Carbamazepine, and Sodium valproate.
Beliefs about Medicines Questionnaire -Specific (BMQ-Specific)
The BMQ-specific (Horne et al., 1999) was used to assess beliefs about medications prescribed for personal use and has been shown to be correlated to adherence (Pakpour et al., 2015) . The measure reflects two domains (necessity and concerns) and each domain is assessed using five items that patients are asked to indicate their agreement with on a 5-point Likert scale (from 1: strongly disagree to 5: strongly agree). The necessity domain assesses patients' beliefs about the necessity of the medication (e.g., Without my medicines I would be very ill), while the concerns domain examines patients' beliefs about the possible adverse effects of the medication (e.g., Having to take medicines worries me). Scores can range between 5 and 25, with higher scores indicating stronger beliefs about the necessity of the medication or a higher level of concern about taking the medicine, respectively. The Persian version of the BMQ has promising psychometric properties and has been used to assess beliefs about medications among an Iranian sample with diabetes (Aflakseir, 2012).
Intention
Patients' intention to take their medication was measured using a questionnaire adapted from Pakpour et al. (Pakpour et al., 2014) . Patients were asked to indicate their agreement with five statements (e.g., I intend to take regular medication in the future) on a 5-point Likert scale
(1: completely disagree to 5: completely agree). Internal consistency of the scale was adequate (Cronbach's =0.91).
Self-monitoring
Self-monitoring was measured by three items (e.g., During the last week, I have consistently monitored when to take my medications, on a 5-point scale from not at all true (1) to exactly true (5) (Pakpour et al., 2015) . Cronbach's for the scale was 0.89.
Self-report Behavioral Automaticity Index (SRBAI)
The SRBAI comprises four items from Self-Report Habit Index (Gardner et al., 2012) , that measure the extent to which relevant behaviors are performed automatically (a key component of habit, (Orbell and Verplanken, 2010) . Each item starts with the stem Behavior X is something…and is followed by (1) I do automatically; (2) I do without having to consciously remember; (3) I do without thinking; and (4) I start doing before I realize I am doing it (Gardner et al., 2012) . All items were rated on a 5-point Likert scale (1: disagree to 5: agree).
Action and coping planning Action planning was measured using four items: I have made a detailed plan regarding when / where / how often / how to take medication. Similarly, coping planning was measured using four items: I have made a detailed plan regarding… (1) what to do if something interferes;
(2) what to do if I forget to take my medication; (3) how to motivate myself if I don't feel like taking my medication; and (4) how to prevent myself from being distracted. All items measuring action planning and coping planning were rated on a 5-point Likert scale (1: completely disagree to 5: completely agree) and showed high levels of internal consistency in the present research (Cronbach's =0.90).
Perceived behavioral control (PBC)
PBC was measured using four items on a 5-point Likert scale (1: completely disagree to 5: completely agree) that have proved internally consistent in the present research (Cronbach's = 0.94). Sample items include: For me to take regular medication in the future is… and It is up to me to take regular medication…
Young Mania Rating Scale (YMRS)
The YMRS contains 11 items each describing a specific mania syndrome. Clinicians were asked to rate how severely the patients have experienced each syndrome within the past 2 days. The items include elevated mood, increased motor and activity-energy, sexual interest, sleep, irritability, speech rate and amount, language/thought disorder, thought content, disruptive/aggressive behavior, appearance, and insight. All items were rated from 0 (absent) to 4 (the highest level), and four of the items (irritability, speech, thought content, and disruptive/aggressive behavior) were double-weighted (McIntyre et al., 2004 , Young et al., 1978 when computing the overall score.
Montgomery Åsberg Depression Rating Scale (MADRS)
The MADRS contains 10-items designed to measure indicators of depression (e.g., reduced appetite). The MADRS is designed to be particularly sensitive to the effects of treatment (such as antidepressants) among people with mood disorders. Clinicians were asked to respond to each of the items on a 7-point scale and total scores could range from 0 (no symptoms of depression) to 60 (highest level of depression (Montgomery and Asberg, 1979) .
Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S)
The CGI-BP-S is modified from Clinical Global Impressions Scale for specific use with patients with BD. The CGI-BP-S comprised three measures to which clinicians were asked to The QoL.BD contains 12 items and is designed to capture patients' subjective perceptions of BD-specific QoL. Each item asks about a specific experience in the past week (e.g., Felt physically well). Patients are asked to respond on a 5-point Likert scale (1: strongly agree to 5: strongly disagree), and a higher score represents a higher level of QoL (Michalak et al., 2010) .
Adverse drug reaction (ADR)
Adverse reactions to the prescribed medications were assessed using a questionnaire adapted from the clinical monitoring form for mood disorders (Sachs et al., 2002) . Patients were asked to indicate the severity of nine side effects (e.g., tremor, dry mouth, etc.) on a five-point Likert scale, ranging from none (0) to severe (4). A total score was computed as the sum of the severity of each side effect and could range from 0 to 36 with higher scores indicating more severe side effects.
Randomization and masking
In order to prevent contamination between the EXP and UC groups, centers were used as unit of randomization rather than patients. Trained professionals at each center (e.g., physicians and nurses) enrolled participants. Centers were allocated in a 1:1 ratio to either the EXP or UC groups by a computer-generated list of random numbers. Five clusters were assigned to the EXP group and 5 clusters to the UC group. Figure 1 illustrates the allocation to condition and the flow of participants through the trial.
Across centers, 538 patients were referred to the trial: 43 declined to be screened for eligibility, 217 did not meet screening criteria, and we lost contact with 8. A total of 270 patients underwent baseline assessment and 134 were randomized to the UC group and 136 to the EXP group. As a result, each center recruited an average of 26 patients. Assessors, psychologists, and psychiatrists were blind to the intervention status of the participants.
Sample Size
The required sample size was calculated based on the primary outcome measure (the MARS). It was estimated that 132 patients would be needed in each condition to detect an effect size of 1 point in the MARS, with 85% power and a significance level of 5%, assuming an intracluster correlation coefficient of 0.05, a mean cluster size equal to 27, and that 10% of the patients would likely be lost to follow up.
Statistical Analysis
Due to the hierarchical nature of the data (i.e., patients were nested within centers), we used multilevel linear mixed modeling to investigate the efficacy of the intervention. Three levels of analysis -time, patients, and centers -were estimated with a restricted iterative generalized least square (RIGLS) estimation. Therefore, for each model, three fixed effects were entered; an intercept term, Time and condition (the UC group served as the reference group).
To decompose the interaction between condition and time, we compared the effects of condition at each time point (i.e., one and six months after treatment) on each dependent variable. The Benjamini and Hochberg false discovery rate was used to adjust p-values for multiple comparisons. In addition, Krull and MacKinnon's three-step recommendations for conducting mediation analyses were performed to identify potential mediators of treatment effects (Krull and MacKinnon, 1999) . All tests were two sided with a significance level of <0.05 and analyses were performed on an intent-to-treat basis using MLwiN 2.27 software. Table 1 summarizes the baseline and clinical characteristics of the two groups. About 51% of the participants in the UC group and 55% of the participants in the EXP group were females and the mean age of the patients was 41.2 (6.4) years in the UC group and 41.8 (8.4) in the EXP group. The mean age of onset of BD was 24 years for both groups. Tables 3 and 4 show the findings of three-level multiple linear regression models examining the effect of the intervention on outcomes. MA improved over time in both the EXP and UC groups. However, scores on the MARS indicated a greater improvement in MA among patients in the EXP group: M baseline = 6.03 (SD = 2.56) and M six months = 9.55 (SD = 3.88); than among patients in the UC group: M baseline = 6.17 (SD = 2.90) and M six months = 6.67 (SD = 2.93). In support of this idea, after taking into account the study center and repeated measurement over time, our multilevel mixed models showed that patients in the EXP group had significantly higher MARS scores than did patients in the UC group both one (B=3.15; p<0.001) and six months (B=3.20; p<0.001) after the intervention (Table 3) . for Sodium valproate; p < 0.001) post-intervention (see Supplementary Table S2) .
Results

Randomization Check
Effects of the Intervention on the Primary Outcome: Medication Adherence
Effects of the Intervention on Secondary Outcomes
Almost all secondary outcomes improved over time in the EXP group (see Table 2 ), and the findings of multiple linear regression models (reported in Tables 3 and 4) show that patients in the EXP group had significantly better outcomes on all secondary measures one month and six months after the intervention, compared with patients in the UC group, except for the measure of quality of life at one month follow-up. Therefore, patients in the EXP group had stronger intentions to take their medication, believe that they had more control over so doing, that taking their medication was more automatic, and were more likely to form action and coping plans to promote MA.
There was also evidence of a decrease in clinical symptoms among patients in the EXP group, relative to patients in the UC group, as shown by significant effects of group on the YMRS (B=-5.32; p<0.001), CGI-BP-S (B=-0.528; p<0.001), and MARDS (B=-4.54; p<0.001).
Furthermore, the quality of life of patients in the EXP group improved significantly more than among patients in the UC group (B=1.17; p=0.025). Table S3 in the supplementary materials shows the direct and mediated effects of group on MA and quality of life (QoL). The effect of the intervention on self-reported MA were mediated by changes in beliefs about medication (i.e., beliefs about the necessity of taking the medication and concern about the possible adverse effects of the medication), intention, selfmonitoring, action planning, and coping planning. In turn, MA mediated the effect of the intervention on QoL.
Mediation Analyses
We also examined whether self-reported MA (i.e., scores on the MARS) mediated the effect of the intervention on plasma levels of mood stabilizers. The results of the mediation analysis indicated that self-reported MA mediated the effect of the intervention on improvements in plasma levels of mood stabilizers. Specifically, scores on the MARS mediated the effect of the intervention effect on improvements in Serum Lithium levels at one month (B= 0.32; SE= 0.10; p<0.001) and six month (B= 0.42; SE= 0.07; p<0.001) follow-ups, improvements in Serum Carbamazepine levels at one month (B= 2.46; SE= 0.36; p<0.001) and six month (B= 2.59; SE= 0.49; p<0.001) follow-ups, and on improvements in Serum Sodium Valproate levels at one month (B= 2.17; SE= 0.68; p<0.001) and six month (B= 1.92; SE= 0.62; p<0.001) follow-ups.
Discussion
The aim of the present research was to assess the efficacy of a multifaceted intervention on MA and health outcomes in patients with BD. We found that a combination of brief sessions of MI, together with psychoeducation and efforts to engage family members in promoting adherence led to significant improvements in objective and self-report measures of MA, as well as in various clinical and functional outcomes compared with usual care. As such, we hope that the findings are informative to mental health clinicians seeking to promote MA among patients with BD and provide a rationale for designing and implementing multifaceted interventions to improve MA in such patients.
A few prior studies have investigated whether interventions based on MI can improve MA in patients with BD. In a quasi-experimental pilot study of 21 elderly subjects with BD, Depp et al. showed that a multifaceted intervention including motivational training improved MA, as well as depressive symptoms and QoL (Depp et al., 2007) . However, this was only a preliminary pilot study with a simple training intervention and a limited outcome measure.
Another study on patients with BD in Iran, showed the effectiveness of an intervention based on psychoeducation. This study included an 18 month follow up and measured quality of life, medication compliance as well as frequency of hospitalization showing considerable improvements in each outcome (Javadpour et al., 2013) .However, the study only involved one center with 108 patients the intervention only used psychoeducation and did not include family members.
In addition to MI, our intervention included other components, namely psychoeducation and engagement of a family member. We found promising effects of the intervention on both self-reported and objective measures of MA. Furthermore, our findings also pointed to improvements in symptoms and QoL, which mediation analyses indicated can be attributed to improved MA.
Strengths and limitations
The present research had several strengths. First, we used both self-report and objective outcome measures to ensure the validity of our findings. Second, using multiple outcome measures targeting different domains allowed us to look at the effect of the intervention on different aspects of health and functioning. Third, we used a multilevel linear mixed model to evaluate the effect of intervention on outcomes.
Our findings should be interpreted in light of some limitations, however. First, family engagement constituted an important component of the intervention in the present research.
While we deem this to be a strength of our multifaceted approach, we acknowledge that family likely plays a more significant role in individuals who live in Middle Eastern cultures than in other, more Western societies (Daneshpour, 1998) . Therefore, the effect of the family component of our intervention might not necessarily be generalizable to other cultures. Second, we did not assess the effect of our intervention beyond six months of follow-up. However, a meta-analysis by MacDonald and colleagues showed that the effects of interventions on MA seemed to be durable for up to two years (MacDonald et al., 2016) . There is no reason to believe that the effects of the present intervention might not also be maintained over this period. Third, it might be argued that a longer intervention might improve adherence rates even further. However, the feasibility of interventions should be considered in term of time and cost as well as efficacy as longer interventions may require greater investment of resources for a relatively small improvement in outcomes. Finally, a natural downside to a multifaceted approach to intervention is that it is difficult to isolate which part of the intervention was most effective. Future research might usefully adopt factorial designs that systematically manipulate and compare different components of the intervention (e.g., the intervention with and without family support) in an effort to identify the active ingredients.
Conclusion
The present findings provide robust evidence that a multifaceted intervention based on MI, psychoeducation, and attempts to engage family members can improve MA among patients with BD. The implication is that health care professionals, especially those who deal with mental health aspects of people with psychiatric disorders such as BD, may use our findings to improve MA and adjust clinical symptoms in their clients. Once trained, the facilitators used the following MI techniques to help the patients to take their medication regularly: Open-ended questions, rolling with resistance, setting agenda and eliciting self-motivational statements, change talk and affirmations.
Tables
The first session was designed to prepare the patient for the MI. The facilitator introduced themselves to the patients and assured them that the conservations would be kept private. Afterward, the facilitator encouraged the patients to discuss and list any concerns that may interfere with their willingness and motivation to receive psychiatric treatment and take medication by asking some basic questions (such as "What do you call your problem?", "What do you think has caused your problem?", and "What do you fear most about your illness?"). Facilitators also provided information on the medication that patients should take (dose and timing, adverse effects, contradictions, and treatment process).
During the second session, the facilitators tried to persuade the patients to commit to change and adhere to the treatment. Open-ended questions (e.g., "So how have things gone this week?" and "How have you been feeling?") were used to assess new stressors and changes in the environment that were likely to affect the patients. The facilitators also inquired about patients' adherence and the response to the medication and helped each patient to weigh up the perceived costs and benefits of taking medication (e.g.,
"What do you see as the positive and negative consequences of taking medication?").
The patient's readiness to change was rated on a scale from 1 (I'm not willing to change) to 10 (I will do anything that I need to change). The importance of taking medicine regularly was also raised by the facilitators and was rated by the patients on a scale from 0 (least important) to 10 (most important). These questions were followed up by openended questions that invited patients to further elaborate on their choices (e.g., "Why did you choose a (current number) instead of a (lower number)?", "What would need to happen to make it a (higher number)?"). The patients were also encouraged to think about what it would be like to make the change by imagining future situations; (e.g., "If you were successful in taking medicine regularly, how would things be different?"
Finally, the facilitators measured and discussed patients' confidence in their ability to change by asking questions such as "On a scale from 0 to 10, where 10 is the most confident and 0 is the least, what number would you give for how confident you are that you could taking medicine regularly?"
The third session addressed potential obstacles to MA. The facilitator helped the patients to review their progress, and sought to renew and reinforce their motivation.
Patients were helped to identify obstacles that might prevent them from taking medication, to identify strategies to overcome obstacles that arise, and to build selfefficacy. In addition, patients were invited to set goals and make plans to support desired changes. Worksheets were given to the patients that encouraged them to identify things that they would need to do to achieve a given goal. The facilitators also encouraged the patients to create an action plan by specifying where, when and how they would take their medication. Patients were also asked to anticipate situations in which it might be difficult to take medication and were encouraged to identify strategies to overcome these barriers (coping planning).
In addition to the MI sessions for the patients, a single MI session was conducted for the family members of the patients in the EXP group. The same facilitators contacted each family member by telephone and invited them to attend a single session. At the beginning of the session, the family members were encouraged to express their feelings about medications and their role in supporting their family members to take their medication regularly was discussed. Barriers and facilitators to behavior change were also explored and the facilitators helped the family members to identify the pros and cons of helping the patients to take their medication regularly. The family members rated the patients' level of commitment and likelihood of success on a 0-10 scale. Family members were encouraged to imagine the patients in the future with and without change. Finally, family members were asked to help their patients to use reminders (such as phone alarm or sticky notes) to improve their MA. 
